BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 235 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q1 2022. The put-call ratio across all filers is 0.62 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $146,973 | -57.1% | 20,759 | -57.4% | 0.00% | -100.0% |
Q2 2023 | $342,705 | -76.1% | 48,680 | -71.7% | 0.00% | -66.7% |
Q1 2023 | $1,435,853 | -17.2% | 172,165 | +14.0% | 0.00% | -25.0% |
Q4 2022 | $1,733,397 | +8.3% | 150,993 | +18.7% | 0.00% | 0.0% |
Q3 2022 | $1,601,000 | -38.8% | 127,175 | -48.6% | 0.00% | -20.0% |
Q2 2022 | $2,617,000 | +100.4% | 247,522 | +207.8% | 0.01% | +150.0% |
Q1 2022 | $1,306,000 | +4564.3% | 80,426 | +3798.5% | 0.00% | – |
Q4 2021 | $28,000 | -3.4% | 2,063 | 0.0% | 0.00% | – |
Q3 2021 | $29,000 | -91.0% | 2,063 | -98.7% | 0.00% | -100.0% |
Q1 2020 | $323,000 | -72.0% | 161,807 | -51.7% | 0.00% | -50.0% |
Q4 2019 | $1,154,000 | +147.6% | 334,725 | +105.9% | 0.00% | +100.0% |
Q3 2019 | $466,000 | +529.7% | 162,545 | +1115.5% | 0.00% | – |
Q2 2017 | $74,000 | -82.3% | 13,373 | -73.1% | 0.00% | -100.0% |
Q1 2017 | $417,000 | +301.0% | 49,638 | +206.4% | 0.00% | – |
Q4 2016 | $104,000 | – | 16,200 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
RP Management, LLC | 3,846,154 | $27,230,770 | 26.28% |
Prosight Management, LP | 2,408,135 | $17,049,596 | 5.40% |
Kynam Capital Management, LP | 3,133,193 | $22,183,006 | 3.63% |
Saturn V Capital Management LP | 982,458 | $6,955,803 | 2.91% |
AlphaCentric Advisors LLC | 649,000 | $4,594,920 | 2.61% |
TANG CAPITAL MANAGEMENT LLC | 1,800,000 | $12,744,000 | 1.80% |
SILVERARC CAPITAL MANAGEMENT, LLC | 791,671 | $5,605,031 | 1.70% |
Eversept Partners, LP | 2,479,103 | $17,552,049 | 1.48% |
DAFNA Capital Management LLC | 652,000 | $4,616,160 | 1.44% |
Avoro Capital Advisors LLC | 11,550,000 | $81,774,000 | 1.28% |